background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

DLL3

Delta-like ligand 3 (DLL3) is an inhibitory protein.1 The Notch pathway is critical for the development and regulation of neuroendocrine versus epithelial cell differentiation in the lungs. DLL3 is typically located in the Golgi apparatus, where it inhibits Notch 1 signaling.1,2

In high-grade neuroendocrine tumors—including small cell lung cancer (SCLC)—DLL3 is highly upregulated and aberrantly expressed on the cell surface, with absent or rare expression on nonmalignant cells.2,3

HLE, half-life extended; NEPC, neuroendocrine prostate cancer.

References
1. Sabari JK, et al. Nat Rev Clin Oncol. 2017;14:549-561. 2. Saunders LR, et al. Sci Transl Med. 2015;7:302ra136. doi:10.1126/scitranslmed.aac9459. 3. Kunninmalaiyaan M, et al. Oncologist. 2007;12:535-542. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04702737. Accessed 4/15/21.
Molecule
Modality4
Target4
Areas of Investigation4,5
AMG 757
Target4
DLL3
Areas of Investigation4,5

HLE, half-life extended; NEPC, neuroendocrine prostate cancer.

References
1. Sabari JK, et al. Nat Rev Clin Oncol. 2017;14:549-561. 2. Saunders LR, et al. Sci Transl Med. 2015;7:302ra136. doi:10.1126/scitranslmed.aac9459. 3. Kunninmalaiyaan M, et al. Oncologist. 2007;12:535-542. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04702737. Accessed 4/15/21.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.